A randomised placebo-controlled trial of oral and topical antibiotics for children with clinically infected eczema in the community: the ChildRen with Eczema, Antibiotic Management (CREAM) study

Nick A Francis,1* Matthew J Ridd,2 Emma Thomas-Jones,3 Victoria Shepherd,3 Christopher C Butler,1,4 Kerenza Hood,3 Chao Huang,3 Katy Addison,3 Mirella Longo,5 Charis Marwick,6 Mandy Wootton,7 Robin Howe,7 Amanda Roberts,8 Mohammed Inaam-ul Haq,3 Vishnu Madhok9 and Frank Sullivan10 on behalf of the CREAM team

1Cochrane Institute of Primary Care and Public Health, School of Medicine, Cardiff University, Cardiff, UK
2Centre for Academic Primary Care, National Institute for Health Research School of Primary Care Research, School of Social and Community Medicine, University of Bristol, Bristol, UK
3South East Wales Trials Unit, School of Medicine, Cardiff University, Cardiff, UK
4Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
5Swansea Centre for Health Economics, Swansea University, Swansea, UK
6Population Health Sciences, School of Medicine, University of Dundee, Dundee, UK
7Specialist Antimicrobial Chemotherapy Unit, Public Health Wales Microbiology Cardiff, University Hospital Wales, Cardiff, UK
8Centre of Evidence Based Dermatology, University of Nottingham, Nottingham, UK
9Park House Surgery, Surrey, UK
10Department of Family and Community Medicine and Dalla Lana School of Public Health, North York General Hospital University of Toronto, Toronto, ON, Canada

*Corresponding author

Declared competing interests of authors: Professor Christopher C Butler received fees for acting in an advisory capacity to Alere™ and is supporting a study on which he is the chief investigator with diagnostic devices in the form of an unconditional educational grant. He is also a National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation board member. Professor Kerenza Hood is a member of the NIHR Clinical Trials Unit standing committee. Dr Mandy Wootton has declared that she received a speakers honoraria from Nordic Pharma Ltd (who manufacture fosfomycin).
Plain English summary

ChildRen with Eczema, Antibiotic Management (CREAM) study
Health Technology Assessment 2016; Vol. 20: No. 19
DOI: 10.3310/hta20190

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Plain English summary

Eczema affects about one in five children in the UK. It tends to come and go, and flare-ups are sometimes triggered by infection. Many doctors give antibiotics for flares, but there is not much evidence to show whether or not they help. The antibiotics can be given as a cream or by mouth.

The ChildRen with Eczema, Antibiotic Management study was designed to find out if antibiotics help improve eczema severity in children with infected eczema flares.

A total of 113 children aged <8 years, with infected eczema, joined the study. Most children had relatively mild or moderate flares. The bacterium *Staphylococcus aureus* (which causes skin infections) was found on most children's skin. Every child was given one of three treatments for 1 week:

1. oral antibiotics and placebo cream
2. antibiotic cream and placebo oral treatment; or
3. double placebo treatment.

All children also received standard eczema treatment with steroid creams/emollients. We collected details about the child's eczema and their general health, eczema severity, daily symptoms, quality of life and impact on the family.

We found that patients in all groups improved by 2 weeks, but patients in both antibiotic groups had slightly worse eczema scores than the placebo group. The difference may have occurred by chance but we can be fairly confident that antibiotics do not reduce eczema severity by a worthwhile amount. They may even make it worse.

We conclude that most children with less severely infected eczema should not be given antibiotics as long as standard treatment (steroid creams/emollients) is offered.
Criteria for inclusion in the Health Technology Assessment journal
Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme
The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report
The research reported in this issue of the journal was funded by the HTA programme as project number 09/118/03. The contractual start date was in June 2012. The draft report began editorial review in July 2015 and was accepted for publication in November 2015. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health.

© Queen’s Printer and Controller of HMSO 2016. This work was produced by Francis et al. under the terms of a commissioning contract issued by the Secretary of State for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
Health Technology Assessment Editor-in-Chief

Professor Hywel Williams  Director, HTA Programme, UK and Foundation Professor and Co-Director of the Centre of Evidence-Based Dermatology, University of Nottingham, UK

NIHR Journals Library Editor-in-Chief

Professor Tom Walley  Director, NIHR Evaluation, Trials and Studies and Director of the HTA Programme, UK

NIHR Journals Library Editors

Professor Ken Stein  Chair of HTA Editorial Board and Professor of Public Health, University of Exeter Medical School, UK

Professor Andree Le May  Chair of NIHR Journals Library Editorial Group (EME, HS&DR, PGfAR, PHR journals)

Dr Martin Ashton-Key  Consultant in Public Health Medicine/Consultant Advisor, NETSCC, UK

Professor Matthias Beck  Chair in Public Sector Management and Subject Leader (Management Group), Queen’s University Management School, Queen’s University Belfast, UK

Professor Aileen Clarke  Professor of Public Health and Health Services Research, Warwick Medical School, University of Warwick

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Peter Davidson  Director of NETSCC, HTA, UK

Ms Tara Lamont  Scientific Advisor, NETSCC, UK

Professor Elaine McColl  Director, Newcastle Clinical Trials Unit, Institute of Health and Society, Newcastle University, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Health Sciences Research, Health and Wellbeing Research and Development Group, University of Winchester, UK

Professor John Norrie  Health Services Research Unit, University of Aberdeen, UK

Professor John Powell  Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Please visit the website for a list of members of the NIHR Journals Library Board: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: nihredit@southampton.ac.uk